https://www.selleckchem.com/products/rmc-9805.html
Elenbecestat, an oral BACE-1 inhibitor that has been shown to reduce Aβ levels in cerebrospinal fluid, was investigated in two global phase 3 studies in early AD. Here we report on differences observed in characteristics of APOE ε4 and amyloid positive subjects in the large screening cohort. Screening was performed in 5 sequential tiers over a maximum of 80 days, as part of placebo controlled, double blind phase 3 studies. Subjects were evaluated at sites in 7 regions (29 countries). Overall, 9758 subjects were screened. All screened s
Like
Comment
Share
